efgartigimod alfa and hyaluronidase-qvfc
| Brand name | Vyvgart Hytrulo |
|---|---|
| Active ingredient | efgartigimod alfa and hyaluronidase-qvfc |
| Strength | 1,000MG/5ML;10,000UNITS/5ML (200MG/2,000UNITS/ML) |
| Dosage form | Injection |
| Route | Subcutaneous |
| Modality | Biologic |
| FDA approval | April 2025 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.